The primary patent for Sanofi's Dupixent (dupilumab) is set to expire in November 2029 [1]. This patent covers the composition of matter for the drug.
When does Dupixent's market exclusivity end?
While the composition of matter patent expires in November 2029, other patents related to Dupixent's use and formulation may extend market exclusivity. The exact end of market exclusivity depends on the lifespan of all relevant patents and potential regulatory exclusivities. Information on specific patent expiration dates for various aspects of Dupixent can be found on resources like DrugPatentWatch.com [1].
What happens when Dupixent's patents expire?
Upon patent expiration, other companies may seek to introduce generic or biosimilar versions of Dupixent to the market. This can lead to increased competition and potentially lower prices for the medication.
How does Dupixent's patent situation compare to other biologics?
Like other biologic drugs, Dupixent has a complex patent landscape. Biologics are typically protected by multiple patents covering different aspects, such as the molecule itself, manufacturing processes, and methods of use. This often results in a longer period of market exclusivity compared to small molecule drugs.
Who are Dupixent's main competitors?
Dupixent is used to treat several inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Competitors in these therapeutic areas vary depending on the specific indication. For example, in atopic dermatitis, other biologics and topical treatments are available [2].
What are the risks associated with Dupixent patent expiration?
For Sanofi, the primary risk is the loss of market exclusivity, which can lead to a significant decrease in sales as biosimilar competitors enter the market. For patients, patent expiration could eventually lead to more affordable treatment options.
What is the regulatory pathway for biosimilars of Dupixent?
Biosimilars of biologics like Dupixent follow a regulatory pathway established by agencies such as the U.S. Food and Drug Administration (FDA). This pathway requires biosimilar manufacturers to demonstrate that their product is highly similar to the reference product (Dupixent) and has no clinically meaningful differences in terms of safety, purity, and potency.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.dupixent.com/